Precision medicine for metastatic breast cancer--limitations and solutions.
Identifieur interne : 002618 ( PubMed/Curation ); précédent : 002617; suivant : 002619Precision medicine for metastatic breast cancer--limitations and solutions.
Auteurs : Monica Arnedos [France] ; Cecile Vicier [France] ; Sherene Loi [Australie] ; Celine Lefebvre [France] ; Stefan Michiels [France] ; Herve Bonnefoi [France] ; Fabrice Andre [France]Source :
- Nature reviews. Clinical oncology [ 1759-4782 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- anatomopathologie : Tumeurs du sein.
- génétique : Tumeurs du sein.
- tendances : Génomique.
- traitement médicamenteux : Tumeurs du sein.
- Femelle, Humains, Médecine individualisée, Métastase tumorale.
English descriptors
- KwdEn :
- MESH :
- drug therapy : Breast Neoplasms.
- genetics : Breast Neoplasms.
- pathology : Breast Neoplasms.
- trends : Genomics.
- Female, Humans, Neoplasm Metastasis, Precision Medicine.
Abstract
The development of precision medicine for the management of metastatic breast cancer is an appealing concept; however, major scientific and logistical challenges hinder its implementation in the clinic. The identification of driver mutational events remains the biggest challenge, because, with the few exceptions of ER, HER2, PIK3CA and AKT1, no validated oncogenic drivers of breast cancer exist. The development of bioinformatic tools to help identify driver mutations, together with assessment of pathway activation and dependency should help resolve this issue in the future. The occurrence of secondary resistance, such as ESR1 mutations, following endocrine therapy poses a further challenge. Ultra-deep sequencing and monitoring of circulating tumour DNA (ctDNA) could permit early detection of the genetic events underlying resistance and inform on combination therapy approaches. Beside these scientific challenges, logistical and operational issues are a major limitation to the development of precision medicine. For example, the low incidence of most candidate genomic alterations hinders randomized trials, as the number of patients to be screened would be too high. We discuss these limitations and the solutions, which include scaling-up the number of patients screened for identifying a genomic alteration, the clustering of genomic alterations into pathways, and the development of personalized medicine trials.
DOI: 10.1038/nrclinonc.2015.123
PubMed: 26196250
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002687
Links to Exploration step
pubmed:26196250Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Precision medicine for metastatic breast cancer--limitations and solutions.</title><author><name sortKey="Arnedos, Monica" sort="Arnedos, Monica" uniqKey="Arnedos M" first="Monica" last="Arnedos">Monica Arnedos</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Vicier, Cecile" sort="Vicier, Cecile" uniqKey="Vicier C" first="Cecile" last="Vicier">Cecile Vicier</name><affiliation wicri:level="1"><nlm:affiliation>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="1"><nlm:affiliation>Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, VIC 3002, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, VIC 3002</wicri:regionArea></affiliation></author><author><name sortKey="Lefebvre, Celine" sort="Lefebvre, Celine" uniqKey="Lefebvre C" first="Celine" last="Lefebvre">Celine Lefebvre</name><affiliation wicri:level="1"><nlm:affiliation>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biostatistics and Epidemiology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Biostatistics and Epidemiology, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Bonnefoi, Herve" sort="Bonnefoi, Herve" uniqKey="Bonnefoi H" first="Herve" last="Bonnefoi">Herve Bonnefoi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and INSERM U916, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology and INSERM U916, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux</wicri:regionArea></affiliation></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="Andre">Fabrice Andre</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26196250</idno><idno type="pmid">26196250</idno><idno type="doi">10.1038/nrclinonc.2015.123</idno><idno type="wicri:Area/PubMed/Corpus">002687</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002687</idno><idno type="wicri:Area/PubMed/Curation">002618</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002618</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Precision medicine for metastatic breast cancer--limitations and solutions.</title><author><name sortKey="Arnedos, Monica" sort="Arnedos, Monica" uniqKey="Arnedos M" first="Monica" last="Arnedos">Monica Arnedos</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Vicier, Cecile" sort="Vicier, Cecile" uniqKey="Vicier C" first="Cecile" last="Vicier">Cecile Vicier</name><affiliation wicri:level="1"><nlm:affiliation>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><affiliation wicri:level="1"><nlm:affiliation>Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, VIC 3002, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, VIC 3002</wicri:regionArea></affiliation></author><author><name sortKey="Lefebvre, Celine" sort="Lefebvre, Celine" uniqKey="Lefebvre C" first="Celine" last="Lefebvre">Celine Lefebvre</name><affiliation wicri:level="1"><nlm:affiliation>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Michiels, Stefan" sort="Michiels, Stefan" uniqKey="Michiels S" first="Stefan" last="Michiels">Stefan Michiels</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biostatistics and Epidemiology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Biostatistics and Epidemiology, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author><author><name sortKey="Bonnefoi, Herve" sort="Bonnefoi, Herve" uniqKey="Bonnefoi H" first="Herve" last="Bonnefoi">Herve Bonnefoi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology and INSERM U916, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology and INSERM U916, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux</wicri:regionArea></affiliation></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="Andre">Fabrice Andre</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif</wicri:regionArea></affiliation></author></analytic><series><title level="j">Nature reviews. Clinical oncology</title><idno type="eISSN">1759-4782</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (genetics)</term><term>Breast Neoplasms (pathology)</term><term>Female</term><term>Genomics (trends)</term><term>Humans</term><term>Neoplasm Metastasis</term><term>Precision Medicine</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Femelle</term><term>Génomique (tendances)</term><term>Humains</term><term>Médecine individualisée</term><term>Métastase tumorale</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (génétique)</term><term>Tumeurs du sein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Génomique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Genomics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Neoplasm Metastasis</term><term>Precision Medicine</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Médecine individualisée</term><term>Métastase tumorale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of precision medicine for the management of metastatic breast cancer is an appealing concept; however, major scientific and logistical challenges hinder its implementation in the clinic. The identification of driver mutational events remains the biggest challenge, because, with the few exceptions of ER, HER2, PIK3CA and AKT1, no validated oncogenic drivers of breast cancer exist. The development of bioinformatic tools to help identify driver mutations, together with assessment of pathway activation and dependency should help resolve this issue in the future. The occurrence of secondary resistance, such as ESR1 mutations, following endocrine therapy poses a further challenge. Ultra-deep sequencing and monitoring of circulating tumour DNA (ctDNA) could permit early detection of the genetic events underlying resistance and inform on combination therapy approaches. Beside these scientific challenges, logistical and operational issues are a major limitation to the development of precision medicine. For example, the low incidence of most candidate genomic alterations hinders randomized trials, as the number of patients to be screened would be too high. We discuss these limitations and the solutions, which include scaling-up the number of patients screened for identifying a genomic alteration, the clustering of genomic alterations into pathways, and the development of personalized medicine trials.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26196250</PMID><DateCreated><Year>2015</Year><Month>11</Month><Day>26</Day></DateCreated><DateCompleted><Year>2016</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4782</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Nature reviews. Clinical oncology</Title><ISOAbbreviation>Nat Rev Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Precision medicine for metastatic breast cancer--limitations and solutions.</ArticleTitle><Pagination><MedlinePgn>693-704</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nrclinonc.2015.123</ELocationID><Abstract><AbstractText>The development of precision medicine for the management of metastatic breast cancer is an appealing concept; however, major scientific and logistical challenges hinder its implementation in the clinic. The identification of driver mutational events remains the biggest challenge, because, with the few exceptions of ER, HER2, PIK3CA and AKT1, no validated oncogenic drivers of breast cancer exist. The development of bioinformatic tools to help identify driver mutations, together with assessment of pathway activation and dependency should help resolve this issue in the future. The occurrence of secondary resistance, such as ESR1 mutations, following endocrine therapy poses a further challenge. Ultra-deep sequencing and monitoring of circulating tumour DNA (ctDNA) could permit early detection of the genetic events underlying resistance and inform on combination therapy approaches. Beside these scientific challenges, logistical and operational issues are a major limitation to the development of precision medicine. For example, the low incidence of most candidate genomic alterations hinders randomized trials, as the number of patients to be screened would be too high. We discuss these limitations and the solutions, which include scaling-up the number of patients screened for identifying a genomic alteration, the clustering of genomic alterations into pathways, and the development of personalized medicine trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arnedos</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicier</LastName><ForeName>Cecile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loi</LastName><ForeName>Sherene</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, VIC 3002, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>Celine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM Unit U981, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michiels</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnefoi</LastName><ForeName>Herve</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology and INSERM U916, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andre</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Clin Oncol</MedlineTA><NlmUniqueID>101500077</NlmUniqueID><ISSNLinking>1759-4774</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cell Cycle. 2014;13(22):3541-50</RefSource><PMID Version="1">25483091</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2015 Feb 19;518(7539):422-6</RefSource><PMID Version="1">25470049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2013 Nov;19(11):1381-8</RefSource><PMID Version="1">24202391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Apr 20;32(12 ):1202-9</RefSource><PMID Version="1">24663045</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Feb 9;366(6):520-9</RefSource><PMID Version="1">22149876</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Jul 1;19(13):3693-702</RefSource><PMID Version="1">23658459</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2014 Jun;20(6):682-8</RefSource><PMID Version="1">24836576</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(1):e53292</RefSource><PMID Version="1">23301057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Oct 20;32(30):3458-9</RefSource><PMID Version="1">25225430</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Nov 27;515(7528):568-71</RefSource><PMID Version="1">25428505</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Genet. 2013 Dec;45(12):1439-45</RefSource><PMID Version="1">24185512</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Aug 14;512(7513):155-60</RefSource><PMID Version="1">25079324</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1987 Jan 9;235(4785):177-82</RefSource><PMID Version="1">3798106</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncoimmunology. 2012 May 1;1(3):271-278</RefSource><PMID Version="1">22737602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 May 20;33(15):1680-7</RefSource><PMID Version="1">25897160</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jun 1;30(16):1996-2004</RefSource><PMID Version="1">22508827</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Viral Hepat. 2015 Feb;22(2):158-65</RefSource><PMID Version="1">24943406</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2014 Jul 08;16(4):R73</RefSource><PMID Version="1">25005255</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2013 Nov;19(11):1401-9</RefSource><PMID Version="1">24202393</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Oct 28;363(18):1734-9</RefSource><PMID Version="1">20979473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 May;15(6):580-91</RefSource><PMID Version="1">24742739</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Discov. 2011 Jun;1(1):44-53</RefSource><PMID Version="1">22586319</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Feb 20;30(6):593-9</RefSource><PMID Version="1">22124109</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2008 Feb;19(2):315-20</RefSource><PMID Version="1">17804473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008 Sep 11;3(9):e3179</RefSource><PMID Version="1">18784837</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Nov;25(11):2244-51</RefSource><PMID Version="1">25193991</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2014 Nov 11;111(10):1881-7</RefSource><PMID Version="1">25225904</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Hum Genet. 2013 Sep 5;93(3):439-51</RefSource><PMID Version="1">23954162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</RefSource><PMID Version="1">12829800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1998 Nov 26;339(22):1609-18</RefSource><PMID Version="1">9828250</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Methods. 2013 Nov;10(11):1081-2</RefSource><PMID Version="1">24037244</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2013 Jul 11;499(7457):214-8</RefSource><PMID Version="1">23770567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Jul 24;376(9737):235-44</RefSource><PMID Version="1">20609467</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jan 20;30(3):282-90</RefSource><PMID Version="1">22162589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Rep. 2014 Jun 26;7(6):1833-41</RefSource><PMID Version="1">24910434</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Discov. 2013 Feb;3(2):224-37</RefSource><PMID Version="1">23220880</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35</RefSource><PMID Version="1">21157483</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Sep;25(9):1729-35</RefSource><PMID Version="1">25009010</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Feb 20;30(6):587-92</RefSource><PMID Version="1">22124102</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jan 1;28(1):92-8</RefSource><PMID Version="1">19933921</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cancer Res. 2013 Oct;11(10 ):1269-78</RefSource><PMID Version="1">23814023</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genome Biol. 2011;12(4):R41</RefSource><PMID Version="1">21527027</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2013 Sep 19;501(7467):355-64</RefSource><PMID Version="1">24048068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Ther. 2015 May;149:124-38</RefSource><PMID Version="1">25512053</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Apr 04;486(7403):395-9</RefSource><PMID Version="1">22495314</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Jan 20;33(3):244-50</RefSource><PMID Version="1">25366685</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2015 Mar 9;27(3):382-96</RefSource><PMID Version="1">25759023</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Mar 28;483(7391):570-5</RefSource><PMID Version="1">22460902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Dec 30;351(27):2817-26</RefSource><PMID Version="1">15591335</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2001 Dec 15;61(24):8647-50</RefSource><PMID Version="1">11751378</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2013 Aug 22;500(7463):415-21</RefSource><PMID Version="1">23945592</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2014 Jun 03;16(3):211</RefSource><PMID Version="1">25093514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2015 Jan;26(1):120-5</RefSource><PMID Version="1">25361980</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Oct 4;490(7418):61-70</RefSource><PMID Version="1">23000897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2015 Aug 15;31(16):2607-13</RefSource><PMID Version="1">25810432</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1973 Oct 12;182(4108):126-34</RefSource><PMID Version="1">4354173</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 May 16;486(7403):400-4</RefSource><PMID Version="1">22722201</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cancer Ther. 2014 May;13(5):1117-29</RefSource><PMID Version="1">24608574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2013 Oct 17;502(7471):333-9</RefSource><PMID Version="1">24132290</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2014 Jul 11;345(6193):216-20</RefSource><PMID Version="1">25013076</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Mar;15(3):267-74</RefSource><PMID Version="1">24508104</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Jan;16(1):25-35</RefSource><PMID Version="1">25524798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Genet. 2013 Dec;45(12):1446-51</RefSource><PMID Version="1">24185510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Genome Res. 2012 Aug;22(8):1589-98</RefSource><PMID Version="1">22759861</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Mar 10;30(8):777-82</RefSource><PMID Version="1">22271473</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2015 Feb 12;518(7538):240-4</RefSource><PMID Version="1">25409150</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Dec 19;347(25):1999-2009</RefSource><PMID Version="1">12490681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2013 May 2;497(7447):108-12</RefSource><PMID Version="1">23563269</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Mar 28;368(13):1199-209</RefSource><PMID Version="1">23484797</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Nov 20;32(33):3753-61</RefSource><PMID Version="1">25332247</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2009 Mar;9(3):153-66</RefSource><PMID Version="1">19238148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2006 Feb 1;66(3):1500-8</RefSource><PMID Version="1">16452206</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Dec 4;371(23 ):2189-99</RefSource><PMID Version="1">25409260</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource><PMID Version="1">24101045</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jun 1;28(16):2784-95</RefSource><PMID Version="1">20404251</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2012 Oct;48(15):2293-9</RefSource><PMID Version="1">22840369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Diagn Pathol. 2013 Aug;17 (4):322-6</RefSource><PMID Version="1">23660273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Oct 1;17 (19):6304-12</RefSource><PMID Version="1">21810918</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26196250</ArticleId><ArticleId IdType="pii">nrclinonc.2015.123</ArticleId><ArticleId IdType="doi">10.1038/nrclinonc.2015.123</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002618 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002618 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26196250
|texte= Precision medicine for metastatic breast cancer--limitations and solutions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26196250" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |